These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 17518123)
41. [The results of the TREAT study: lessons and limitations]. Del Vecchio L G Ital Nefrol; 2010; 27(1):3. PubMed ID: 20191449 [No Abstract] [Full Text] [Related]
43. The KDIGO anemia guideline: can reason triumph over regulation? Wish JB Nephrol News Issues; 2012 Dec; 26(13):20, 22-3. PubMed ID: 23346853 [No Abstract] [Full Text] [Related]
44. The TREAT study answers a question, not the question. Coyne DW Am J Kidney Dis; 2008 Sep; 52(3):626-7; author reply 627-8. PubMed ID: 18725019 [No Abstract] [Full Text] [Related]
45. ESAs further restricted, but debate continues. Brower V J Natl Cancer Inst; 2008 Oct; 100(19):1344-51. PubMed ID: 18812542 [No Abstract] [Full Text] [Related]
46. [Erythropoietin, chronic renal failure and cancer]. Robles Perez-Monteoliva NR Med Clin (Barc); 2016 Jun; 146(12):539-40. PubMed ID: 26832198 [No Abstract] [Full Text] [Related]
47. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care. Fatodu H Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875 [TBL] [Abstract][Full Text] [Related]
49. Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. Bennett CL; Lai SY; Sartor O; Georgantopoulos P; Hrushesky WJ; Henke M; Armitage JO JAMA Oncol; 2016 Jan; 2(1):134-6. PubMed ID: 26606114 [No Abstract] [Full Text] [Related]
50. Full results on risks of epoetin emerge 14 years after major dialysis study. Epstein K BMJ; 2012 May; 344():e3535. PubMed ID: 22619221 [No Abstract] [Full Text] [Related]
51. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R; Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642 [TBL] [Abstract][Full Text] [Related]
53. Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe? Steensma DP Am J Hematol; 2009 Jan; 84(1):3-5. PubMed ID: 19037863 [No Abstract] [Full Text] [Related]
54. FDA finalizes REMS program for ESAs; Amgen continues to study risks. Brower V J Natl Cancer Inst; 2010 May; 102(9):592-3. PubMed ID: 20421565 [No Abstract] [Full Text] [Related]
55. [Would prescription of erythropoiesis-stimulating agents in pre-dialysis change after results from TREAT study?]. Alcázar R; Tato A; García F; Barrios V; Quereda C Nefrologia; 2010; 30(1):114-8. PubMed ID: 20038963 [No Abstract] [Full Text] [Related]
56. On peginesatide and anemia treatment in CKD. Parfrey PS; Warden G; Barrett BJ Am J Kidney Dis; 2013 Oct; 62(4):659-61. PubMed ID: 23810692 [No Abstract] [Full Text] [Related]
57. New limits advised for anemia drugs. Mitka M JAMA; 2008 May; 299(17):2016. PubMed ID: 18460658 [No Abstract] [Full Text] [Related]
58. Erythropoietin in cancer patients. Glaspy JA Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468 [TBL] [Abstract][Full Text] [Related]
59. Use of erythropoietins in patients with renal transplants. Treleaven DJ; Clase CM BMJ; 2009 Oct; 339():b3825. PubMed ID: 19854838 [No Abstract] [Full Text] [Related]
60. Finding the magic formula for ESA use. Neumann ME Nephrol News Issues; 2010 May; 24(6):8. PubMed ID: 20509399 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]